IP Library › Patent Application 18651565
Patent Application
App. No. 18/651,565

NUCLEIC ACID POLYMERASE FOR INCORPORATING LABELED NUCLEOTIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/651,565
Abstract

Mutant nucleic acid polymerases are described herein. Also described are methods for screening or assaying the mutant nucleic acid polymerases.

Claims (42)

1 . A nucleic acid polymerase, comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1, wherein the polymerase comprises a mutation, relative to SEQ ID NO: 1, at an amino acid position selected from the group consisting of 495, 515, 526-534, 538, 549, 551-568, 570-590, 609-630, 635-637, 640, 655-663, 674, 681, 683, 688, 689, 701, 703-720, 728-730, 743, 761, 770-829, 872, and 873, wherein the amino acid position numbering is according to SEQ ID NO: 2.

2 . The polymerase of claim 1 , wherein the mutation is at amino acid position 495, 515, 529, 531, 538, 549, 558, 559, 561, 562, 563, 564, 565, 566, 567, 568, 572, 573, 575, 579, 580, 583, 622, 623, 628, 629, 630, 635, 636, 637, 640, 655, 660, 661, 662, 674, 681, 683, 688, 689, 701, 703, 704, 707, 710, 713, 716, 718, 743, 761, 780, 782, 785, 786, 788, 800, 806, 815, 819, 826, 827, 872, or 873.

3 . The polymerase of claim 2 , wherein the mutation is V495F, E515K, N529R, P531Q, L538F, K549I, A558M, D559K, D559R, D559S, L561I, E562N, K563G, L564V, A565R, P566L, Y567H, H568P, E572D, N573E, L575I, Q579N, L580D, L580G, L583N, L583V, N622G, E623Y, I628L, I628M, R629A, L630D, L630P, K635S, I636M, I636L, R637M, F640V, S655N, R660C, V661I, L662M, A674V, I681V, T683K, T683V, D688M, I689F, I689Q, I689V, I689Y, M701L, R703A, R703H, R703P, Q704I, A707Y, F710Y, V713M, I716Q, D718A, D718K, F743R, F743Y, G761E, N780K, N782R, N782V, S785R, F786R, E788R, A800G, K806E, K806M, L815F, R819K, R819M, R819P, R819V, L826Y, Q827D, W872H, or Y873D.

4 . The polymerase of claim 1 , wherein the polymerase comprises at least two mutations, relative to SEQ ID NO: 1, at amino acid positions selected from the group consisting of 495, 515, 526-534, 538, 549, 551-568, 570-590, 609-630, 635-637, 640, 655-663, 674, 681, 683, 688, 689, 701, 703-720, 728-730, 743, 761, 770-829, 872, and 873.

5 . The polymerase of claim 4 , wherein the at least two mutations are at amino acid positions 495, 515, 529, 531, 538, 549, 558, 559, 561, 562, 563, 564, 565, 566, 567, 568, 572, 573, 575, 579, 580, 583, 622, 623, 628, 629, 630, 635, 636, 637, 640, 655, 660, 661, 662, 674, 681, 683, 688, 689, 701, 703, 704, 707, 710, 713, 716, 718, 743, 761, 780, 782, 785, 786, 788, 800, 806, 815, 819, 826, 827, 872, or 873.

6 . The polymerase of claim 5 , wherein the at least two mutations comprise two or more of V495F, E515K, N529R, P531Q, L538F, K549I, A558M, D559K, D559R, D559S, L561I, E562N, K563G, L564V, A565R, P566L, Y567H, H568P, E572D, N573E, L575I, Q579N, L580D, L580G, L583N, L583V, N622G, E623Y, I628L, I628M, R629A, L630D, L630P, K635S, I636M, I636L, R637M, F640V, S655N, R660C, V661I, L662M, A674V, 1681V, T683K, T683V, D688M, I689F, I689Q, I689V, I689Y, M701L, R703A, R703H, R703P, Q704I, A707Y, F710Y, V713M, I716Q, D718A, D718K, F743R, F743Y, G761E, N780K, N782R, N782V, S785R, F786R, E788R, A800G, K806E, K806M, L815F, R819K, R819M, R819P, R819V, L826Y, Q827D, W872H, or Y873D.

7 . The polymerase of any one of claims 1-6 , wherein the amino acid sequence comprises at least 95% identity to SEQ ID NO: 2.

8 . The polymerase of any one of claims 1-6 , wherein the amino acid sequence further comprises a DNA binding domain.

9 . The polymerase of claim 8 , wherein the DNA binding domain comprises a sequence at least 95% identical to SEQ ID NO: 4 or SEQ ID NO: 5.

10 . The polymerase of claim 8 , wherein the DNA binding domain comprises a sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

11 . The polymerase of any one of claims 8-10 , wherein the DNA binding domain is attached to the N-terminus of a polymerase domain.

12 . The polymerase of claim 11 , wherein the DNA binding domain is attached to the N-terminus of the polymerase domain through an amino acid linker.

13 . A nucleic acid polymerase, comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3, wherein the polymerase comprises a mutation, relative to SEQ ID NO: 3, at an amino acid position selected from the group consisting of 495, 515, 526-534, 538, 549, 551-568, 570-590, 609-630, 635-637, 640, 655-663, 674, 681, 683, 688, 689, 701, 703-720, 728-730, 743, 761, 770-829, 872, and 873, wherein the amino acid position numbering is according to SEQ ID NO: 2.

14 . The polymerase of claim 13 , wherein the mutation is at amino acid position 495, 515, 529, 531, 538, 549, 558, 559, 561, 562, 563, 564, 565, 566, 567, 568, 572, 573, 575, 579, 580, 583, 622, 623, 628, 629, 630, 635, 636, 637, 640, 655, 660, 661, 662, 674, 681, 683, 688, 689, 701, 703, 704, 707, 710, 713, 716, 718, 743, 761, 780, 782, 785, 786, 788, 800, 806, 815, 819, 826, 827, 872, or 873, wherein the amino acid position numbering is according to SEQ ID NO: 2.

15 . The polymerase of claim 13 , wherein the mutation is V495F, E515K, N529R, P531Q, L538F, K549I, A558M, D559K, D559R, D559S, L561I, E562N, K563G, L564V, A565R, P566L, Y567H, H568P, E572D, N573E, L575I, Q579N, L580D, L580G, L583N, L583V, N622G, E623Y, I628L, I628M, R629A, L630D, L630P, K635S, I636M, I636L, R637M, F640V, S655N, R660C, V661I, L662M, A674V, I681V, T683K, T683V, D688M, I689F, I689Q, I689V, I689Y, M701L, R703A, R703H, R703P, Q704I, A707Y, F710Y, V713M, I716Q, D718A, D718K, F743R, F743Y, G761E, N780K, N782R, N782V, S785R, F786R, E788R, A800G, K806E, K806M, L815F, R819K, R819M, R819P, R819V, L826Y, Q827D, W872H, or Y873D, wherein the amino acid position numbering is according to SEQ ID NO: 2.

16 . The polymerase of claim 13 , wherein the polymerase comprises at least two mutations, relative to SEQ ID NO: 1, at amino acid positions selected from the group consisting of 495, 515, 526-534, 538, 549, 551-568, 570-590, 609-630, 635-637, 640, 655-663, 674, 681, 683, 688, 689, 701, 703-720, 728-730, 743, 761, 770-829, 872, and 873, wherein the amino acid position numbering is according to SEQ ID NO: 2.

17 . The polymerase of claim 16 , wherein the at least two mutations are at amino acid positions 495, 515, 529, 531, 538, 549, 558, 559, 561, 562, 563, 564, 565, 566, 567, 568, 572, 573, 575, 579, 580, 583, 622, 623, 628, 629, 630, 635, 636, 637, 640, 655, 660, 661, 662, 674, 681, 683, 688, 689, 701, 703, 704, 707, 710, 713, 716, 718, 743, 761, 780, 782, 785, 786, 788, 800, 806, 815, 819, 826, 827, 872, or 873, wherein the amino acid position numbering is according to SEQ ID NO: 2.

18 . The polymerase of claim 16 , wherein the at least two mutations comprise two or more of V495F, E515K, N529R, P531Q, L538F, K549I, A558M, D559K, D559R, D559S, L561I, E562N, K563G, L564V, A565R, P566L, Y567H, H568P, E572D, N573E, L575I, Q579N, L580D, L580G, L583N, L583V, N622G, E623Y, I628L, I628M, R629A, L630D, L630P, K635S, I636M, I636L, R637M, F640V, S655N, R660C, V661I, L662M, A674V, I681V, T683K, T683V, D688M, I689F, I689Q, I689V, I689Y, M701L, R703A, R703H, R703P, Q704I, A707Y, F710Y, V713M, I716Q, D718A, D718K, F743R, F743Y, G761E, N780K, N782R, N782V, S785R, F786R, E788R, A800G, K806E, K806M, L815F, R819K, R819M, R819P, R819V, L826Y, Q827D, W872H, or Y873D, wherein the amino acid position numbering is according to SEQ ID NO: 2.

19 . The polymerase of any one of claims 1-18 , wherein the polymerase comprises a mutation at amino acid position 628, wherein the amino acid position numbering is according to SEQ ID NO: 2.

20 . The polymerase of claim 19 , wherein the polymerase comprises a I628L mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

21 . The polymerase of claim 20 , wherein the polymerase comprises a 785R mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

22 . The polymerase of any one of claims 1-18 , wherein the polymerase comprises a mutation at amino acid position 630, wherein the amino acid position numbering is according to SEQ ID NO: 2.

23 . The polymerase of claim 22 , wherein the polymerase comprises a L630D mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

24 . The polymerase of claim 22 , wherein the polymerase comprises a L630P mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

25 . The polymerase of any one of claims 1-18 , wherein the polymerase comprises a mutation at amino acid position 785, wherein the amino acid position numbering is according to SEQ ID NO: 2.

26 . The polymerase of claim 25 , wherein the polymerase comprises an S785R mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

27 . The polymerase of any one of claims 1-18 , wherein the polymerase comprises a mutation at amino acid position 827, wherein the amino acid position numbering is according to SEQ ID NO: 2.

28 . The polymerase of claim 27 , wherein the polymerase comprises a Q827D mutation, wherein the amino acid position numbering is according to SEQ ID NO: 2.

29 . A composition comprising the polymerase of any one of claims 1-28 , and an aqueous solution.

30 . The composition of claim 29 , further comprising nucleotides and a nucleic acid hybrid comprising a target nucleic acid molecule hybridized to a sequencing primer.

31 . The composition of claim 30 , wherein at least a portion of the nucleotides are labeled nucleotides.

32 . The composition of claim 31 , wherein the labeled nucleotides comprise a fluorescent label.

33 . A nucleic acid molecule encoding the polymerase of any one of claims 1-28 .

34 . An expression vector comprising the nucleic acid molecule of claim 33 .

35 . A host cell, comprising the expression vector of claim 34 .

36 . A method of making a polymerase, comprising:

culturing the host cell of claim 35 ;

expressing, using the host cell, the polymerase; and

isolating the polymerase.

37 . A method, comprising: providing in a reaction mixture (i) a nucleic acid molecule, (ii) a labeled nucleotide, and (iii) the mutant polymerase of any one of claims 1-28 , under conditions sufficient to extend the nucleic acid molecule with the labeled nucleotide.

38 . A method, comprising: contacting a labeled nucleotide with the mutant polymerase of any one of claims 1-28 and extending a nucleic acid molecule to incorporate the labeled nucleotide.

39 . The method of claims 37 or 38 , wherein said labeled nucleotide comprises a fluorescent dye.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2026
From: ULTIMA GENOMICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 075435/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2024
From: MAZUR, DANIEL; TOZER, EILEEN COLLINS; NIKIFOROV, THEO; TOPACIO-HALL, DENISE SANCHEZ
To: ULTIMA GENOMICS, INC.
Reel/Frame 067301/0131 →